ConductScience.org, home

Comparison · NCT04605159-5937949a

RSV MAT Group - Infant vs Placebo Group - Infant: Number of Infant Participants With All-cause Pneumonia From Birth to Day 181 Post-birth

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. RSV MAT Group - Infant vs Placebo Group - Infant: Number of Infant Participants With All-cause Pneumonia From Birth to Day 181 Post-birth. Trial comparisons, record NCT04605159-5937949a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04605159-5937949a

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01050.00760.0145wilson
Risk in group 20.009940.006210.0159wilson
Risk difference, group 1 minus group 20.000572-0.006020.00604newcombe hybrid score
Risk ratio, group 1 over group 21.060.5961.88log
Odds ratio, group 1 over group 21.060.5931.89log
Number needed to treat, for one more participant with the outcome on RSV MAT Group - Infant than on Placebo Group - Infant1,750from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1RSV MAT Group - InfantThis group consisted of infants born to mothers (from RSV MAT Group - Mother) who received a single dose of RSV MAT vaccine during pregnancy.363,426OG000
Group 2Placebo Group - InfantThis group consisted of infants born to mothers (from Placebo Group - Mother) who received a single dose of placebo during pregnancy.171,711OG001

Outcome

Type
SECONDARY
Title
Number of Infant Participants With All-cause Pneumonia From Birth to Day 181 Post-birth
Description
The number of infant participants with all-cause pneumonia is presented in this outcome measure.
Time frame
From birth to Day 181 post-birth
Population
The analysis was performed on the Modified Full Analysis - Efficacy set for infants, which included all infant participants in the Exposed Set who were born after at least 4 weeks of their maternal participants vaccination.

Source ClinicalTrials.gov

Trial

Title
A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers
NCT number
NCT04605159
Phases
PHASE3
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT, Placebo
Lead sponsor
GlaxoSmithKline
Results first posted
2024-09-05

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04605159-5937949a